Small Molecules in Parkinson’s Disease Therapy
Author Information
Author(s): Lee Hwayoung, Elkamhawy Ahmed, Rakhalskaya Polina, Lu Qili, Nada Hossam, Quan Guofeng, Lee Kyeong
Primary Institution: BK21 FOUR Team and Integrated Research, Institute for Drug Development, College of Pharmacy, Dongguk University-Seoul
Hypothesis
Can small molecules targeting dopamine pathways and other emerging targets improve Parkinson's disease therapy?
Conclusion
The review highlights both established and emerging therapeutic strategies for Parkinson's disease, emphasizing the potential of small molecules to improve treatment outcomes.
Supporting Evidence
- Parkinson's disease affects approximately 10 million people worldwide.
- Current therapies primarily focus on symptom alleviation rather than disease modification.
- Recent research has identified additional molecular factors contributing to Parkinson's disease pathology.
Takeaway
This study looks at how new small medicines might help people with Parkinson's disease by focusing on different ways to treat it, not just the usual ones.
Methodology
The review categorizes therapeutic targets into currently used therapies and those under active research, focusing on small-molecule compounds studied from 2019 to 2023.
Limitations
The review does not provide specific clinical trial data or detailed statistical analyses of the discussed compounds.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website